High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 - PubMed (original) (raw)
Clinical Trial
. 2000 Jun;18(12):2444-58.
doi: 10.1200/JCO.2000.18.12.2444.
Affiliations
- PMID: 10856105
- DOI: 10.1200/JCO.2000.18.12.2444
Clinical Trial
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
J M Kirkwood et al. J Clin Oncol. 2000 Jun.
Abstract
Purpose: Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs).
Patients and methods: A prospective, randomized, three-arm, intergroup trial evaluated the efficacy of high-dose IFNalpha2b (HDI) for 1 year and low-dose IFNalpha2b (LDI) for 2 years versus Obs in high-risk (stage IIB and III) melanoma with RFS and OS end points.
Results: A total of 642 patients were enrolled (608 patients eligible), of whom a majority (75%) had nodal metastasis (50% had nodal recurrence). Unlike E1684, E1690 allowed entry of patients with T4 (> 4 mm) deep primary tumors, regardless of nodal dissection, and 25% of the patients entered onto this trial had deep primary tumors (compared with 11% in E1684). At 52 months' median follow-up, HDI demonstrated an RFS benefit exceeding that of LDI compared with Obs. The 5-year estimated RFS rates for the HDI, LDI, and Obs arms were 44%, 40%, and 35%, respectively. The hazards ratio for the intent-to-treat analysis of HDI versus Obs was 1.28 (P(2) =.05); for LDI versus Obs, it was 1.19 (P(2) =.17). By Cox analysis, the impact of HDI on RFS achieved significance (P(2) =.03). The RFS benefit was equivalent for node-negative and node-positive patients. Neither HDI nor LDI has demonstrated an OS benefit compared with Obs at this time. A major improvement in the median OS of patients in the E1690 Obs arm was noted in comparison with E1684 (6 years v 2.8 years). An analysis of salvage therapy for patients who relapsed on E1690 demonstrated that a significantly larger proportion of patients in the Obs arm received IFNalpha-containing salvage therapy compared with the HDI arm; this therapy was unavailable to patients during E1684, and patients with undissected regional nodes were not included in E1684. This study did not specify therapy at recurrence. Analysis of treatments received at recurrence demonstrated significantly more frequent use of IFNalpha2b at relapse from Obs than from HDI, which may have confounded interpretation of the survival benefit of assigned treatments in E1690.
Conclusion: The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.
Comment in
- Adjuvant therapy of melanoma: at what cost?
Spitler LE. Spitler LE. J Clin Oncol. 2001 Feb 15;19(4):1226-8. doi: 10.1200/JCO.2001.19.4.1226. J Clin Oncol. 2001. PMID: 11181688 No abstract available.
Similar articles
- A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. Kirkwood JM, et al. Clin Cancer Res. 2004 Mar 1;10(5):1670-7. doi: 10.1158/1078-0432.ccr-1103-3. Clin Cancer Res. 2004. PMID: 15014018 Clinical Trial. - An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG, Puligandla M, Lee SJ, Kirkwood JM. Najjar YG, et al. Cancer. 2019 Sep 1;125(17):3013-3024. doi: 10.1002/cncr.32162. Epub 2019 May 8. Cancer. 2019. PMID: 31067358 Free PMC article. - High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. Kirkwood JM, et al. J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370. J Clin Oncol. 2001. PMID: 11331315 Clinical Trial. - Adjuvant Therapy for Melanoma.
Agha A, Tarhini AA. Agha A, et al. Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5. Curr Oncol Rep. 2017. PMID: 28417343 Review. - The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
Trinh VA, Zobniw C, Hwu WJ. Trinh VA, et al. Expert Opin Drug Saf. 2017 Aug;16(8):933-940. doi: 10.1080/14740338.2017.1343301. Epub 2017 Jun 30. Expert Opin Drug Saf. 2017. PMID: 28627943 Review.
Cited by
- Oxidized Melanoma Antigens Promote Activation and Proliferation of Cytotoxic T-Cell Subpopulations.
Clemen R, Miebach L, Singer D, Freund E, von Woedtke T, Weltmann KD, Bekeschus S. Clemen R, et al. Adv Sci (Weinh). 2024 Sep;11(33):e2404131. doi: 10.1002/advs.202404131. Epub 2024 Jul 3. Adv Sci (Weinh). 2024. PMID: 38958560 Free PMC article. - A Joint Model Based on Post-Treatment Longitudinal Prognostic Nutritional Index to Predict Survival in Nasopharyngeal Carcinoma.
Hsiao PW, Wang YM, Wu SC, Chen WC, Wu CN, Chiu TJ, Yang YH, Luo SD. Hsiao PW, et al. Cancers (Basel). 2024 Mar 3;16(5):1037. doi: 10.3390/cancers16051037. Cancers (Basel). 2024. PMID: 38473396 Free PMC article. - Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.
Eljilany I, Castellano E, Tarhini AA. Eljilany I, et al. Cancers (Basel). 2023 Aug 16;15(16):4125. doi: 10.3390/cancers15164125. Cancers (Basel). 2023. PMID: 37627153 Free PMC article. Review. - Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma.
García-Ortega MB, Aparicio E, Griñán-Lisón C, Jiménez G, López-Ruiz E, Palacios JL, Ruiz-Alcalá G, Alba C, Martínez A, Boulaiz H, Perán M, Hackenberg M, Bragança J, Calado SM, Marchal JA, García MÁ. García-Ortega MB, et al. Cancers (Basel). 2023 Jul 18;15(14):3666. doi: 10.3390/cancers15143666. Cancers (Basel). 2023. PMID: 37509327 Free PMC article. - Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis.
Ba H, Zhu F, Zhang X, Mei Z, Zhu Y. Ba H, et al. Ther Adv Med Oncol. 2023 Jan 24;15:17588359221148918. doi: 10.1177/17588359221148918. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743526 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical